New ADHD Drug Subsidized, Australia

April 18, 2007 – 10:35 am | posted in ADHD

A new drug for the treatment of attention deficit hyperactivity disorder (ADHD) will be listed from 1 July 2007 on the Pharmaceutical Benefits Scheme (PBS).

The drug, Strattera® (atomoxetine), will provide treatment for children between the ages of six and 18 years who cannot take stimulants.

ADHD is a behavioural and developmental disorder that affect young children. The main symptoms of ADHD - inattention, hyperactivity and impulsivity - contribute to adverse academic and social behaviour, which can have consequences that persist throughout adolescence and into adulthood.

Treatment for ADHD normally involves stimulant therapy, so the listing of Strattera® on the PBS will especially benefit those who are unable to take stimulants.

About 18,000 people will commence Strattera® in the first full financial year of listing.

The listing of Strattera® will add around $101.2 million to PBS and Repatriation Pharmaceutical Benefits Scheme expenditure between 2007-08 and 2010-11.

ShareThis

Also Read

  • Does Omega 3 Protect Against ADHD?
  • ADHD In Adults Can Hurt Job Performance, Relationships
  • ADHD’s Role In Smoking Examined By Columbia Study
  • Shire Analysis Compares Stimulant To Nonstimulant ADHD Medications In Patients Aged 8 To 15 Years
  • NIH Supports Research On ADHD - Alcohol Abuse Connection, Could Lead To New Treatments For Adult ADHD
  • ADHD Medication Being Discontinued By Many Children
  • Concerta Showed Significant Improvement Of ADHD Symptom Management In Adults, New Study Finds
  • Getting SAD Is More Than Having The Blues
  • Most People In Massachusetts Must Be Insured Or Face Tax Penalties
  • Is ADHD Properly Diagnosed And Treated In Adults?

    • You must be logged in to post a comment.